Study Examines the Impact of Legal Access to Medical Cannabis on Nonmedical Prescription Opioid Use
A recent study found that the legalization of medical cannabis in the United States was associated with a slight decrease in nonmedical prescription opioid use.
Citing the inconclusive current research on legalization of medical cannabis and its effect on nonmedical prescription opioid (NMPO) use, a recent study examined data from the 2004–2014 National Surveys on Drug Use and Health from adults ages 21 and older with NMPO use (1). The study titled, “Association Between Legal Access to Medical Cannabis and Frequency of Non-Medical Prescription Opioid Use Among U.S. Adults,” was published in the International Journal of Mental Health and Addiction on October 30th, 2023 (1). Researchers concluded that medical cannabis laws (MCL) were associated with a slight decrease in NMPO use (2).
After analyzing the data, researchers found that as a state legalized medical cannabis, there was a 0.5 to 1.5 percentage point decrease in regular to frequent NMPO use and a 2.1 percent point increase in occasional NMPO use (2). They also found that the most significant changes came only from those who had cannabis use disorder (CUD) (1). In those cases, frequent opioid use dropped 4.9 percentage points (3).
“The association of MCL with lower frequency of NMPO use was driven by individuals with cannabis use disorder, highlighting the importance of identifying tradeoffs of cannabis legalization as an intervention to reduce opioid-related harms,” the authors stated in the abstract (1).
In the face of the rising opioid-related deaths in the US, cannabis has been explored as a possible aid to reducing opioid addiction (2).
“There might be some benefits to allowing legal access to medical cannabis in the context of opioid-related harms,” stated Hillary Samples, lead author of the study (2). “However, from a policy perspective, there are much more effective interventions to address the ongoing overdose crisis, such as increasing access to treatment for opioid addiction.”
References
- Samples, H.; Levy, N. S.; Bruzelius, E.; Segura, L. E.; Mauro, P. M.; Boustead, A. E.; Mauro, C. M.; Martins, S. S. Association between legal access to medical cannabis and frequency of non-medical prescription opioid use among U.S. adults. International Journal of Mental Health and Addiction 2023 DOI: 10.1007/s11469-023-01191-y.
- Swenarton, N. States with legalized medical marijuana see decline in nonmedical opioid use https://www.rutgers.edu/news/states-legalized-medical-marijuana-see-decline-nonmedical-opioid-use (accessed Nov 15, 2023).
- Adlin, B. Medical marijuana legalization led to reduction in frequent use of nonmedical prescription opioids, study finds https://www.marijuanamoment.net/medical-marijuana-legalization-led-to-reduction-in-frequent-use-of-nonmedical-prescription-opioids-study-finds/ (accessed Nov 15, 2023).
Empowering Women in Cannabis: Susan Audino, PhD, on Inclusivity, Integrity, and Industry Challenges
December 11th 2024Founder of S. A. Audino & Associates, LLC, Susan Audino, PhD, recently co-founded Saturn Scientific, LLC, a collaboration of five experienced individuals providing unbiased evaluations on the data and science for stakeholders in the cannabis industry. In this interview with Cannabis Science and Technology, Dr. Audino shares her unexpected path into analytical science and the cannabis industry as well as the obstacles she’s faced throughout her career. She highlights the gender bias she’s observed, such as unequal recognition of credentials and workplace challenges, while advocating for inclusivity and mentorship to empower women in science. Additionally, Dr. Audino recounts her experiences of navigating the male-dominated cannabis space, pushing for transparency, collaboration, and integrity in laboratory practices. Ultimately, Audino believes fostering mutual respect and knowledge-sharing is vital for the industry’s growth and resilience.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
